196 related articles for article (PubMed ID: 8027413)
1. Comparison of bupropion and trazodone for the treatment of major depression.
Weisler RH; Johnston JA; Lineberry CG; Samara B; Branconnier RJ; Billow AA
J Clin Psychopharmacol; 1994 Jun; 14(3):170-9. PubMed ID: 8027413
[TBL] [Abstract][Full Text] [Related]
2. Fluoxetine versus trazodone: efficacy and activating-sedating effects.
Beasley CM; Dornseif BE; Pultz JA; Bosomworth JC; Sayler ME
J Clin Psychiatry; 1991 Jul; 52(7):294-9. PubMed ID: 2071559
[TBL] [Abstract][Full Text] [Related]
3. A comparative, randomized, double-blind study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder.
Munizza C; Olivieri L; Di Loreto G; Dionisio P
Curr Med Res Opin; 2006 Sep; 22(9):1703-13. PubMed ID: 16968574
[TBL] [Abstract][Full Text] [Related]
4. Fluoxetine versus trazodone in the treatment of outpatients with major depression.
Debus JR; Rush AJ; Himmel C; Tyler D; Polatin P; Weissenburger J
J Clin Psychiatry; 1988 Nov; 49(11):422-6. PubMed ID: 3053668
[TBL] [Abstract][Full Text] [Related]
5. A comparison of venlafaxine, trazodone, and placebo in major depression.
Cunningham LA; Borison RL; Carman JS; Chouinard G; Crowder JE; Diamond BI; Fischer DE; Hearst E
J Clin Psychopharmacol; 1994 Apr; 14(2):99-106. PubMed ID: 8195464
[TBL] [Abstract][Full Text] [Related]
6. Double-blind comparison of doxepin versus bupropion in outpatients with a major depressive disorder.
Feighner J; Hendrickson G; Miller L; Stern W
J Clin Psychopharmacol; 1986 Feb; 6(1):27-32. PubMed ID: 3081600
[TBL] [Abstract][Full Text] [Related]
7. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
Hewett K; Chrzanowski W; Schmitz M; Savela A; Milanova V; Gee M; Krishen A; Millen L; Leary MO; Modell J
J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
9. A comparative trial of fluoxetine versus trazodone in outpatients with major depression.
Perry PJ; Garvey MJ; Kelly MW; Cook BL; Dunner FJ; Winokur G
J Clin Psychiatry; 1989 Aug; 50(8):290-4. PubMed ID: 2668259
[TBL] [Abstract][Full Text] [Related]
10. Long-term therapy for depression with trazodone.
Fabre LF; Feighner JP
J Clin Psychiatry; 1983 Jan; 44(1):17-21. PubMed ID: 6337131
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
Perahia DG; Pritchett YL; Kajdasz DK; Bauer M; Jain R; Russell JM; Walker DJ; Spencer KA; Froud DM; Raskin J; Thase ME
J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
[TBL] [Abstract][Full Text] [Related]
12. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
[TBL] [Abstract][Full Text] [Related]
13. Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms.
Jain AK; Kaplan RA; Gadde KM; Wadden TA; Allison DB; Brewer ER; Leadbetter RA; Richard N; Haight B; Jamerson BD; Buaron KS; Metz A
Obes Res; 2002 Oct; 10(10):1049-56. PubMed ID: 12376586
[TBL] [Abstract][Full Text] [Related]
14. Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women.
Gadde KM; Parker CB; Maner LG; Wagner HR; Logue EJ; Drezner MK; Krishnan KR
Obes Res; 2001 Sep; 9(9):544-51. PubMed ID: 11557835
[TBL] [Abstract][Full Text] [Related]
15. Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder.
Alpert JE; Franznick DA; Hollander SB; Fava M
J Clin Psychiatry; 2004 Aug; 65(8):1069-75. PubMed ID: 15323591
[TBL] [Abstract][Full Text] [Related]
16. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
[TBL] [Abstract][Full Text] [Related]
17. Bupropion may support psychosocial treatment of nicotine-dependent adolescents: preliminary results.
Niederhofer H; Huber M
Pharmacotherapy; 2004 Nov; 24(11):1524-8. PubMed ID: 15537557
[TBL] [Abstract][Full Text] [Related]
18. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
19. Trazodone in the treatment of neurotic depression.
Goldberg HL; Finnerty RJ
J Clin Psychiatry; 1980 Dec; 41(12 Pt 1):430-4. PubMed ID: 7440519
[TBL] [Abstract][Full Text] [Related]
20. [Review of studies of trazodone at the Feighner Research Institute in ambulatory and hospitalized patients].
Feighner JP
Encephale; 1986 Oct; 12 Spec No():243-8. PubMed ID: 3816685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
